Histone deacetylase inhibition and the regulation of cell growth with particular reference to liver pathobiology.
The transcriptional activity of genes largely depends on the accessibility of specific chromatin regions to transcriptional regulators. This process is controlled by diverse post-transcriptional modifications of the histone amino termini of which reversible acetylation plays a vital role. Histone acetyltransferases (HATs) are responsible for the addition of acetyl groups and histone deacetylases (HDACs) catalyse the reverse reaction. In general, though not exclusively, histone acetylation is associated with a positive regulation of transcription, whereas histone deacetylation is correlated with transcriptional silencing. The elucidation of unequivocal links between aberrant action of HDACs and tumorigenesis lies at the base of key scientific importance of these enzymes. In particular, the potential benefit of HDAC inhibition has been confirmed in various tumour cell lines, demonstrating antiproliferative, differentiating and pro-apoptotic effects. Consequently, the dynamic quest for HDAC inhibitors (HDIs) as a new class of anticancer drugs was set off, resulting in a number of compounds that are currently evaluated in clinical trials. Ironically, the knowledge with respect to the expression pattern and function of individual HDAC isoenzymes remains largely elusive. In the present review, we provide an update of the current knowledge on the involvement of HDACs in the regulation of fundamental cellular processes in the liver, being the main site for drug metabolism within the body. Focus lies on the involvement of HDACs in the regulation of growth of normal and transformed hepatocytes and the transdifferentiation process of stellate cells. Furthermore, extrapolation of our present knowledge on HDAC functionality towards innovative treatment of malignant and non-malignant, hyperproliferative and inflammatory disorders is discussed.
Joanna
Fraczek
F
Department of Toxicology, Vrije Universiteit Brussel, Laarbeeklaan, Brussels, Belgium. jfraczek@vub.ac.be
van Grunsven
Leo A
LA
Mathieu
Vinken
V
Sarah
Snykers
S
Sarah
Deleu
D
Karin
Vanderkerken
V
Tamara
Vanhaecke
V
Vera
Rogiers
R
D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000378:metabolism; D049109:Cell Proliferation; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000378:metabolism; D005355:Fibrosis / Q000473:pathology; D022781:Hepatocytes / Q000166:cytology; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology*; D006655:Histone Deacetylases / Q000378:metabolism*; D006657:Histones / Q000378:metabolism; D006801:Humans; D007249:Inflammation; D008099:Liver / Q000473:pathology / Q000503:physiopathology*; D008954:Models, Biological; D012175:Retinoblastoma / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D056572:Histone Deacetylase Inhibitors; D006657:Histones; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D006655:Histone Deacetylases